Logo

Verona Pharma’s Ohtuvayre (Ensifentrine) Receives the US FDA's Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

Share this
Verona Pharma

Verona Pharma’s Ohtuvayre (Ensifentrine) Receives the US FDA's Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

Shots: 

  • The US FDA has approved Ohtuvayre as a maintenance therapy to treat COPD patients, with its launch anticipated in Q3’24 

  • The approval was based on the P-III (ENHANCE-1 & ENHANCE-2) studies analyzing Ohtuvayre monotx. or in addition with other maintenance therapies. Trials reached their 1EPs showing improved lung function; results were published in the American Journal of Respiratory and Critical Care Medicine 

  • Ohtuvayre is a dual PDE3 & PDE4 inhibitor which possesses both bronchodilator & non-steroidal anti-inflammatory activities. It is administered using a standard jet nebulizer into the lungs  

Ref: Verona Pharma | Image: Verona Pharma

Related Post:- Verona Pharma Reports the US FDA Acceptance of NDA for Ensifentrine to Treat Chronic Obstructive Pulmonary Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions